Clinical Trial Results: Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating pioglitazone to reduce sympathetic overactivity in chronic kidney disease patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: The University of Texas at Arlington | Conditions: Chronic Kidney Diseases | Phase 4 | Status: TERMINATED | Results posted: 2026-07-27